Kornimate/medical-research-clean huggingface dataset:
the value of diagnosis and outcome prediction in ctc for metastatic npc patients

Conditions: Nasopharyngeal Neoplasms

Summary: a circulating tumor cell (ctc) count is an established prognostic factor in some malignancies such as metastatic breast cancer. however, the value of ctc in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma (mnpc) patients is not unknown. through the observational prospective clinical trial, sensitivity, specificity, positive and negative predictive values of ctc in diagnosis of mnpc patients will be gained. further, the value of ctc in outcome prediction of mnpc patients will be uncovered.


Eligibility criteria:
inclusion criteria: * histologically or radiologically confirmed nasopharyngeal non-keratinizing carcinoma (who ii, iii). * npc patients with distant metastasis including synchronous distant metastasis at diagnosis and metachronous distant metastasis after radical treatment. * a karnofsky performance status score more than 70. * the participants provided written informed consent. exclusion criteria: * a history of previous or synchronous malignant tumors. * suffering from severe mental illness synchronously. * suffering from severe heart or lung diseases. * obvious abnormality in liver and renal function. * women in pregnancy or breastfeeding.

Keywords: nasopharyngeal carcinoma distant metastasis circulating tumor cells outcome prediction
a study of ly3295668 erbumine in participants with breast cancer that has spread to other parts of the body

Conditions: Metastatic Breast Cancer

Summary: the reason for this study is to determine the recommended phase 2 dose of the study drug ly3295668 erbumine in participants with breast cancer that has spread to other parts of the body.


Eligibility criteria:
inclusion criteria: * participant must have hormone receptor positive and her2 negative metastatic breast cancer * participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (cdk)4/6 inhibitor * participant must be able and willing to undergo mandatory tumor biopsy * participant must have normal organ function * participant must be able to swallow capsules exclusion criteria: * participant must not have had prior chemotherapy for mbc. chemotherapy in the adjuvant/neoadjuvant setting is permitted * participant must not be currently enrolled in a clinical study * participant must not have another serious medical condition * participant must not have previously received an aurora kinase inhibitor

Keywords: aurora kinase a kinase aurora a aurora kinase inhibitor aurora kinase a inhibitor kinase inhibitor aurka aura
understanding loss of muscle mass and function

Conditions: Sarcopenia

Summary: sarcopenia is a loss of muscle mass and function that develops during aging. but sarcopenia is also observed in several other conditions: chronic diseases, cancers, viral infections, renal / respiratory insufficiency, immobility, obesity with low physical activity. this sarcopenia is named secondary sarcopenia to distinguish it from the age-associated primary sarcopenia. during prolonged hospitalizations in intensive care, a significant loss of muscular mass and function is also observed. this acute sarcopenia or intensive care unit-acquired weakness (icu-aw) may persist for several months after discharge from hospital. in addition to the loss of autonomy, the reduction of muscle mass has important metabolic implications, ranging from insulin resistance to modification of myokines production. sarcopenia greatly increases the morbidity and mortality of patients regardless of its cause. the aim of our project is to identify the molecular mechanisms implicated in sarcopenia from different origin. we will particularly focus our work on the metabolic properties, the proliferation/ differentiation and regeneration capacities of the satellite cells (adult muscle stem cells). these satellite cells will be purified from quadriceps biopsies of human volunteers recruited at chu montpellier. these satellite cells will also be used to test the ability of some wild aromatic plants from south of france to improve cell survival and differentiation. this will allow us to identify the molecular mechanisms involved in sarcopenia development and identify potential therapeutic molecules.


Eligibility criteria:
inclusion criteria: * patients undergoing quadriceps muscle biopsy as part of the treatment. * patient having given their agreement of conservation within the framework of the care of the biological sample (biopsy and blood sample) exclusion criteria: * subject refusing the detection of anti-hiv, anti-hepatitis c antibodies, hbs antigen * subject treated with anticoagulant, beta blocker, lipid-lowering agent (statin or fibrate), anti-inflammatory, ace inhibitors, angiotensin 2 receptor antagonist or corticosteroids, including locally. * allergic subject to local anesthetics * history or presence of psychoactive substance abuse * history of recent abdominal surgery (less than 3 months) * subject deprived of liberty by judicial or administrative decision * major subject protected by law * inability to understand the nature and purpose of the study and / or communication difficulties with the investigator

Keywords: satellite cells therapeutic aromatic plants
the effect of gm-csf to preventing oral mucositis for patients with nasopharyngeal carcinoma receiving radiotherapy

Conditions: GM-CSF

Summary: to evaluate the efficacy of gm-csf to preventing oral mucositis for patients with nasopharyngeal carcinoma receiving radiotherapy.

patients of gm-csf group receive gm-csf washmouth four times a day during radiotherapy. control arm receive conventioanl care during radiotherapy. visual signs of radiation or chemotherapy-induced mucosal damage were independently assessed during the course of rt by a radiation oncologist or other trained study personnel. the incidence of severe oral mucositis, the severe oral mucositis last time, quality of life between the two arms would be calculated.

Eligibility criteria:
inclusion criteria: * a. patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma (including differentiated type and undifferentiated type, world health organization \[who\] ii or iii). b. original clinical staged as ii-iva (according to the 8 th ajcc edition) c. male or female who are not pregnant. d. no evidence of distant metastasis (m0). e. age between 18-65 years. f. wbc≥4×109/l, plt≥100×109/l, hgb≥90g/l. g. normal liver function test: alanine aminotransferase (alt), aspartate aminotransferase (ast) \<1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤2.5×uln, and bilirubin ≤uln. i. with normal renal function test (creatinine clearance rate≥60 ml/min or creatinine\< 1.5×uln. j. the eastern cooperative oncology group (ecog) performance status less or equal to 1. k. patients must be informed of the investigational nature of this study and give written informed consent. l. patients receive induction chemotherapy plus concurrent chemoradiotherpy or concurrent chemoradiotherapy, or radiotherapy alone. exclusion criteria: * age \ 65years. c. with clinical stage of i or ivb (according to the 8 th ajcc edition). d. patients with tumor recurrence or distant metastasis. e. prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. f. history of previous radiotherapy (except for non-melanomatous skin cancers outside intended rt treatment volume). g. prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. h. pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period). i. any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, acute exacerbation of chronic obstructive pulmonary disease or other respiratory illness requiring admission to hospital, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×uln), and mental disturbance.

Keywords: nasopharyngeal carcinoma gm-csf oral mucositis
ed50 of esketamine for laser treatment in children

Conditions: Anesthesia

Summary: there is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. we explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients.


Eligibility criteria:
inclusion criteria: * age between 3 years and 12 years old * patients scheduled for laser treatment of facial lesion exclusion criteria: * patients with airway infection during the last 1 month * patients with cardiac or pulmonary disorder * patients with hepatic or renal disfunction * patients with neurologic or psychiatric disorder

Keywords: esketamine children half effective dose laser treatment
defining benchmarks for gastric cancer patients underwent minimal invasive gastrectomy

Conditions: Gastric Adenocarcinoma; Surgery, Laparoscopic

Summary: the benchmark-misgc study was a large-scale retrospective observational study launched by the china gastric cancer surgical union, aiming to establish the benchmarks of the short- and long-term outcomes for gastric cancer patients who underwent minimal invasive gastrectomy.


Eligibility criteria:
inclusion criteria: 1. patients with postoperative histologically confirmed gastric adenocarcinoma at stages t1-4a, n0/+, m0; 2. underwent robotic or laparoscopic gastrectomies with curative intent exclusion criteria: 1. asa class \> 3; 2. remnant gastric cancer; 3. concurrent/previous malignant disease; 4. distant metastasis; 5. palliative resection; 6. abodominal exploration.
neurotoxicity and cardiotoxicity in total joint arthroplasty

Conditions: Metallosis; Pain; Total Hip Replacement; Total Knee Replacement

Summary: the purpose of this research is to understand whether patients who previously had total hip or total knee replacement experience memory, thinking or heart problems. this study will help us determine if and how often these problems occur.

at your first visit you will be asked to do the following. * sign this informed consent document. * questionnaire: you will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities. * interview: the interview will be performed by the study coordinator who is a member of the research team. it will take about 20-30 minutes to complete. you will be asked to answer questions about your general health, surgeries, medications, and your memory and thinking skills. * memory interview: you will have an evaluation of your memory and thinking skills. you will answer questions and perform tasks that evaluate various thinking abilities such as concentration, memory, reasoning, and learning. * blood draw: have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests. * magnetic resonance imaging (mri) of your brain (optional): if you agree to participate, you will be asked to have mr imaging of your brain. * echocardiogram: you will be asked to have an echocardiogram of your heart. * follow-up visit in 2-3 years: you will be asked to return to mayo for your second study visit in 2-3 years. at this visit, you will be asked to complete the same memory and thinking tests described for the first visit. you will also be asked to repeat the echocardiogram.

Eligibility criteria:
inclusion criteria: * patient is willing to sign consent * patients scheduled for revision surgery for osteolysis, aseptic loosening, or wear of tja implants/altr. or -mcsa (mayo clinic study of aging) patients with tha or tka with at least 10 years since surgery. exclusion criteria: * history of dementia * history of cardiomyopathy or heart failure * revision for infection or fracture * patient is pregnant * patient has medication patches on * patient has a pacemaker or defibrillator (icd) * patient has a deep brain stimulator (dbs) * patient has a vagal neuro stimulator (vns) * patient has any other kind of neuro stimulator * patient has aneurysm clips in their head * patient has a tissue expander * patient has had a gastrointestinal clip or pill camera inserted in the last 90 days * patient has an esophageal reflux management system (linx) * patient has a cochlear (ear) or auditory implant * patient has any implanted device (electronic or not) with magnets * patient has an eye injury involving metal * patient has allergy to contrast or dye

Keywords: revision surgery hip knee metals metallosis toxicity
ultrasonographic evaluation of internal jugular vein cross sectional area for prediction of post spinal hypotension

Conditions: Post-spinal Anesthesia Hypotension

Summary: the aim of this study is to evaluate the efficacy of internal jugular cross sectional area for predicting the occurrence of psah.

the aim of this study is to evaluate the efficacy of internal jugular cross sectional area for predicting the occurrence of psah. spinal anaesthesia is frequently used in daily clinical practice. postspinal anaesthesia hypotension (psah) is a common side effect with an incidence of 15.3 to 33% that may result in organ hypoperfusion and ischaemic events. patients' susceptibility to intraoperative hypotension can be influenced by the sensory block level, age, preoperative volume status , physical status, pre-operative medications and fasting. psah due to spinal blockade is principally a consequence of diminished systemic vascular resistance after blockade of preganglionic sympathetic fibres. many attempts have been tried to prevent psah, such as intravenous volume preload or prophylactic vasopressors. however, fluid infusion has been proved to lower the incidence of psah and significantly decrease vasopressor requirements. at the same time, empirical volume loading carries the potential of volume overload, particularly in patients with cardiac disease. consequently, the search for predictors of psah is becoming mandatory to avoid blind volume loading and reserve it only for patients who are expected to develop psah. . .

Eligibility criteria:
inclusion criteria: * patients more than 40 years of age. * american society of anesthesiologists' (asa) physical status 1 or 2. * scheduled for elective surgery under spinal anaesthesia in the supine position. exclusion criteria: * bmi more than 35 kg m2. * taking angiotensin converting enzyme inhibitors. * pregnant women. * emergency cases. * absolute or relative contraindications to spinal anaesthesia. * also, patients with a baseline arterial systolic blood pressure less than 90 mmhg or mean arterial blood pressure (mbp) less than 70 mmhg will be excluded.

Keywords: internal jugular vein ultrasound spinal anesthesia hypotension
effects of comprehensive augmented and virtual reality in stroke patients

Conditions: Stroke

Summary: the purpose of this study was to assess the efficacy of augmented and virtual reality-based rehabilitation programs on improving upper extremity function in subacute stroke patients.

this was a randomized, single-blinded study, conducted at a single acute rehabilitation unit in a university hospital. in this study, the effect of augmented and virtual reality-based rehabilitation for the recovery of subacute stroke patients compared with conventional occupational therapy was evaluated.

Eligibility criteria:
inclusion criteria: * first ever stroke * onset of stroke less than 3 months * sufficiently medically stable to participate in active rehabilitation * mild-to-moderate upper extremity motor impairments (brunnstrom stage for the upper extremity 2-6). exclusion criteria: * severe cognitive impairment (defined as score \< 10 on the mini-mental state examination) * evidence of apraxia * clinical history of neglect * previous upper extremity hemiplegia.

Keywords: virtual reality augmented reality
comparison of three kinds of postoperative analgesia after total knee arthroplasty

Conditions: Pain; Complications

Summary: postoperative pain after total knee arthroplasty (tka) can be difficult to manage and may delay recovery. there are multimodal postoperative pain management after tka, including intravenous opioids, epidural analgesia, peripheral nerve blocks or periarticular infiltration with local anesthetics. all of these treatments may lead to side effects such as nausea, headache, hypotension, urinary retention, partial motor block and infection of the knee. therefore the investigators will compare three methods of postoperative analgesic after tka by their efficiency and complication.


Eligibility criteria:
inclusion criteria: 1. patients of american association of anesthetists（asa）grade 1、2 or 3 2. aged between 18 and 85 years 3. undergoing elective total knee replacement exclusion criteria: 1. mental illness can not match 2. nerve block, epidural anesthesia contraindicated 3. people who have slow-type arrhythmias 4. history of chronic headaches and long-term use of analgesic drugs 5. people who were postoperative consciousness, language or hearing impaired

Keywords: local analgesia system ropivacaine analgesic efficacy after operation postoperative
a study of palifermin for the reduction of oral mucositis in patients with locally advanced head and neck cancer receiving postoperative radiotherapy and concurrent chemotherapy

Conditions: Mucositis; Head and Neck Cancer

Summary: oral mucositis associated with adjuvant radiation and concurrent chemotherapy in postoperative head and neck setting

this study consisted of 2 phases. the acute oral mucositis (om) evaluation phase includes the time from randomization to the time of severe om (who grade 3 or 4) resolution (up to week 12 or up to week 15 for participants whose severe om is not resolved at week 12). in the acute om evaluation phase, participants were randomized to receive either a single iv bolus dose of palifermin or placebo at 120 μg/kg, 3 days before the start of radiotherapy, plus 7 once-weekly palifermin or placebo doses at the same dose level during a 7-week radio/chemotherapy course. in the long-term follow up phase, participants are followed until death, withdrawal of consent, or loss to follow-up. the long-term follow up phase is still ongoing.

Eligibility criteria:
inclusion criteria: * history of newly diagnosed histologically confirmed squamous cell carcinoma (american joint committee on cancer \[ajcc\] stage ii, iii, iva, or ivb) involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx, post surgical resection (r0, r1) * scheduled to receive adjuvant concurrent chemoradiation treatment within 12 weeks of surgery * high-risk subject defined by presence of at least one of the following: r1 resection margins; t3 or t4 tumor stage; 3 or more positive lymph node metastases; \<3 lymph node metastases with extracapsular extension of the disease * radiation treatment field to receive planned dose of at least 50gy to areas of the oral cavity/oropharynx mucosa that can be visualized exclusion criteria: * tumors of the lips, paranasal sinuses, salivary glands, or of unknown primary tumors * metastatic disease (m1) / stage iv c * presence or history of any other primary malignancy * history of pancreatitis * prior radiotherapy to the site of disease * prior chemotherapy * other investigational procedures * thirty days or less since receiving an investigational product or device in another clinical trial. current enrollment in another clinical trial is not permitted unless the sole purpose of the trial is for long-term follow-up/survival data

Keywords: palifermin clinical trial oncology head & neck
oxygen saturation alarms in the neonatal intensive care unit

Conditions: Hypoxemia

Summary: infants will be observed in the neonatal intensive care unit for 4 hours. the observer will note the timing of oxygen saturation alarms, staff response, and interrupted staff activities.

false alarms may be particularly prevalent in the neonatal intensive care unit (nicu) where uncontrolled motion of infants can intensify the problem. the performance of pulse oximeters is of particular importance in the nicu because of the danger that both hyperoxemia and hypoxemia pose to newborns; hyperoxemia can lead to chronic lung disease or retinopathy of prematurity, and hypoxemia depresses spontaneous ventilation. high false alarm rates contribute to the problem of noise in the nicu. they also have the potential to endanger patients if clinicians become inured to the continual alarms and ignore some that may be clinically relevant. there have been few studies on the utility of pulse oximeter alarms in the nicu, particularly with the new-generation technology. this study will build on the small body of existing literature on alarm rates in new-generation pulse oximeters in neonates and provide details about the relationship of the alarms to clinical interventions. this is an observational study of 50 infants at three hospitals in the united states. the observer will be an experienced nurse with comprehensive training to ensure consistency. the infants and clinical staff will be observed for four hours continuously. observers will note the timing of alarms, response, interrupted clinical staff activities, and any clinical interventions, and timing of interventions. clinical staff will also be questioned on whether the alarm was consistent with a desaturation event. infant characteristics may affect the frequency of alarms. data collected will include age, gender, weight, ethnicity, diagnosis, and medications. this study will evaluate the proportion of nuisance alarms relative to the proportion of clinically relevant alarms. it will also evaluate the differences in alarm frequencies across infant characteristics and characterize nurse activities interrupted by the alarms.

Eligibility criteria:
inclusion criteria: * infants in the nicu continuously monitored by pulse oximetry exclusion criteria: * infants whose legal guardians do not consent

Keywords: neonatal intensive care infant pulse oximetry